CO2021014353A2 - Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav - Google Patents
Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aavInfo
- Publication number
- CO2021014353A2 CO2021014353A2 CONC2021/0014353A CO2021014353A CO2021014353A2 CO 2021014353 A2 CO2021014353 A2 CO 2021014353A2 CO 2021014353 A CO2021014353 A CO 2021014353A CO 2021014353 A2 CO2021014353 A2 CO 2021014353A2
- Authority
- CO
- Colombia
- Prior art keywords
- cas9
- cells
- rnp
- car
- primary
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 101150038500 cas9 gene Proteins 0.000 title 1
- 210000000822 natural killer cell Anatomy 0.000 title 1
- 108091033409 CRISPR Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000010354 CRISPR gene editing Methods 0.000 abstract 1
- 102000004389 Ribonucleoproteins Human genes 0.000 abstract 1
- 108010081734 Ribonucleoproteins Proteins 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825007P | 2019-03-27 | 2019-03-27 | |
| PCT/US2020/025454 WO2020198675A1 (en) | 2019-03-27 | 2020-03-27 | Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021014353A2 true CO2021014353A2 (es) | 2022-01-17 |
Family
ID=72611833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0014353A CO2021014353A2 (es) | 2019-03-27 | 2021-10-26 | Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12655449B2 (enExample) |
| EP (1) | EP3946432A4 (enExample) |
| JP (2) | JP7702878B2 (enExample) |
| KR (1) | KR20220017887A (enExample) |
| CN (1) | CN113891727A (enExample) |
| AU (1) | AU2020248097B2 (enExample) |
| BR (1) | BR112021019180A2 (enExample) |
| CA (1) | CA3135198A1 (enExample) |
| CO (1) | CO2021014353A2 (enExample) |
| IL (1) | IL286701A (enExample) |
| MX (1) | MX2021011782A (enExample) |
| PH (1) | PH12021552383A1 (enExample) |
| SG (1) | SG11202110613SA (enExample) |
| WO (1) | WO2020198675A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466867B2 (en) | 2018-02-21 | 2025-11-11 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021372458A1 (en) * | 2020-10-26 | 2023-06-15 | Research Institute At Nationwide Children's Hospital | Chimeric antigen receptor (car) nk cells and uses thereof |
| WO2022236174A1 (en) * | 2021-05-07 | 2022-11-10 | Washington University | In situ car-t therapies, vectors and methods therefor |
| CN117716024A (zh) * | 2021-06-01 | 2024-03-15 | 瓦克斯细胞生物 | 包含饲养细胞的自然杀伤细胞增殖用组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE051612T2 (hu) * | 2012-07-11 | 2021-03-01 | Sangamo Therapeutics Inc | Eljárások és készítmények lizoszomális tárolási betegségek kezelésére |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| PL3298134T3 (pl) | 2015-05-16 | 2023-09-18 | Genzyme Corporation | Edycja genów mutacji głęboko intronowych |
| US11911415B2 (en) * | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
| WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
| CN110267978A (zh) | 2016-10-07 | 2019-09-20 | 得克萨斯大学体系董事会 | 用于治疗癌症的表达膜锚定的il-12的t细胞 |
| EP3532075A4 (en) | 2016-10-27 | 2020-07-08 | Intima Bioscience, Inc. | VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS |
| JP2020518245A (ja) | 2017-05-03 | 2020-06-25 | サンガモ セラピューティクス， インコーポレイテッド | 嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物 |
| EP4775669A2 (en) * | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| SG11202007288VA (en) | 2018-01-30 | 2020-08-28 | Res Institute At Nationwide Children’S Hospital | Transforming growth factor beta-resistant natural killer cells |
| CN108504685A (zh) * | 2018-03-27 | 2018-09-07 | 宜明细胞生物科技有限公司 | 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法 |
| AU2019271366B2 (en) | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
-
2020
- 2020-03-27 MX MX2021011782A patent/MX2021011782A/es unknown
- 2020-03-27 AU AU2020248097A patent/AU2020248097B2/en active Active
- 2020-03-27 BR BR112021019180A patent/BR112021019180A2/pt unknown
- 2020-03-27 JP JP2021557392A patent/JP7702878B2/ja active Active
- 2020-03-27 KR KR1020217034800A patent/KR20220017887A/ko active Pending
- 2020-03-27 CN CN202080036500.4A patent/CN113891727A/zh active Pending
- 2020-03-27 PH PH1/2021/552383A patent/PH12021552383A1/en unknown
- 2020-03-27 WO PCT/US2020/025454 patent/WO2020198675A1/en not_active Ceased
- 2020-03-27 US US17/598,619 patent/US12655449B2/en active Active
- 2020-03-27 CA CA3135198A patent/CA3135198A1/en active Pending
- 2020-03-27 EP EP20777892.9A patent/EP3946432A4/en active Pending
- 2020-03-27 SG SG11202110613SA patent/SG11202110613SA/en unknown
-
2021
- 2021-09-26 IL IL286701A patent/IL286701A/en unknown
- 2021-10-26 CO CONC2021/0014353A patent/CO2021014353A2/es unknown
-
2025
- 2025-06-24 JP JP2025106768A patent/JP2025160172A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466867B2 (en) | 2018-02-21 | 2025-11-11 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020248097A1 (en) | 2021-11-18 |
| PH12021552383A1 (en) | 2022-06-13 |
| JP2022527709A (ja) | 2022-06-03 |
| US12655449B2 (en) | 2026-06-16 |
| BR112021019180A2 (pt) | 2022-03-03 |
| MX2021011782A (es) | 2021-12-10 |
| EP3946432A4 (en) | 2023-04-05 |
| US20220177917A1 (en) | 2022-06-09 |
| SG11202110613SA (en) | 2021-10-28 |
| AU2020248097B2 (en) | 2026-05-21 |
| IL286701A (en) | 2021-10-31 |
| EP3946432A1 (en) | 2022-02-09 |
| JP7702878B2 (ja) | 2025-07-04 |
| WO2020198675A1 (en) | 2020-10-01 |
| JP2025160172A (ja) | 2025-10-22 |
| CA3135198A1 (en) | 2020-10-01 |
| KR20220017887A (ko) | 2022-02-14 |
| CN113891727A (zh) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011782A (es) | Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav. | |
| CL2020001992A1 (es) | Composiciones de virus adeno-asociadas para la transferencia de genes pah y métodos de uso de los mismos | |
| MX2024008058A (es) | Adenovirus modificados. | |
| CL2019000124A1 (es) | Anticuerpos anti-virus del zika y métodos de uso. | |
| CL2022001374A1 (es) | Receptores de antígeno quimérico y usos de los mismos | |
| AU2018254566A1 (en) | Oncolytic virotherapy and immunotherapy | |
| CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| CL2017000438A1 (es) | Sistema de señalización | |
| HK1258041A1 (zh) | 免疫细胞组合物和使用方法 | |
| AU2017257169A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| EA201791381A1 (ru) | Универсальная клетка т-киллер | |
| AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
| CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
| CL2016002333A1 (es) | Terapia genica para la retinitis pigmentaria. | |
| MX2017007575A (es) | Receptores de antígenos quiméricos de antígeno de maduración de células b. | |
| AR115069A1 (es) | Virus vacuna quimérico sintético | |
| MX2020013017A (es) | Materiales y metodos para tratar cancer. | |
| MX2016010324A (es) | Sistema y metodo para efectuar remesas. | |
| MX387985B (es) | Particulas tipo virus modificadas de cmv. | |
| BR112019012158A2 (pt) | vacinação eficaz contra cepas europeias de vírus da síndrome reprodutiva e respiratória suína (prrs) antes do desmame | |
| PE20230433A1 (es) | Composiciones de virus adenoasociados para restaurar la funcion del gen pah y los metodos de uso de estas | |
| MX2021004993A (es) | Materiales y metodos para tratar cancer. | |
| CO2020010793A2 (es) | Composiciones de virus adeno-asociado para restaurar la función del gen pah y métodos de uso de las mismas | |
| BR112021024855A2 (pt) | Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas | |
| UY37198A (es) | Vacuna universal para enfermedades virales |